According to the new catalogue,11drugs were added to the national medical insurance, and three drugs were transferred out. After adjustment, the total number of drugs in the national medical insurance drug list is 2967, including western medicine 1586 and Chinese medicine 138 1 drug. There are also 892 kinds of Chinese herbal pieces.
The National Medical Insurance Bureau introduced at the press conference on the adjustment of medical insurance drug list on June 5438+1October 65438+1October 8 that this round of national medical insurance drug list adjustment, the national medical insurance information platform * * * received 537 enterprises' declaration information, involving 490 drugs, and 344 drugs passed the preliminary examination, with a passing rate of 70%. Judging from the negotiation and bidding, 147 drugs out of the catalogue participated in the negotiation and bidding, and 12 1 drug negotiation or bidding was successful, with an overall winning rate of 82.3%.
"One more small step will benefit more patients" and "our goal is the same". On October 5-8, 2023/KLOC-0, the newspaper noticed that many negotiators mentioned this statement at the medical insurance negotiation site of the Beijing National People's Congress Conference Center. 10 days later, with the dust of the 2022 version of the medical insurance catalogue settled, the results of the national medical insurance drug negotiation in 2022 were officially announced.
Two COVID-19 oral drugs were successfully negotiated.
Huang Xinyu, deputy director of the Medical Service Management Department of the National Medical Insurance Bureau, said that for the third consecutive year, the National Medical Insurance Bureau took the new crown treatment drugs as the access conditions of the medical insurance catalogue, and two drugs, such as Ajifu tablets and Qingfei Jiedu granules, will be formally included in the national medical insurance drug catalogue through negotiations. Of the 25 listed drugs involved in the tenth edition of COVID-19's infection diagnosis and treatment plan, 2 1 variety has been officially included in the national medical insurance catalogue.
Previously, three COVID-19 therapeutic drugs, Afuddin from real bioses, Nimatevir/Ritonavir from Pfizer and Qingfei Paidu Granule from Institute of Clinical Basic Medicine of Chinese Academy of Traditional Chinese Medicine, participated in the negotiation of national medical insurance catalogue.
According to media reports, the negotiation result of Avdine is that the price of 3mg is reduced by about 35%, and it will be included in the medical insurance at the price of 1 1.58 yuan/tablet. The new standard of afudin is 1mg. According to the drug price difference specification, the standard price should be lowered to 4.99 yuan/tablet, that is, the price of afudin for treatment in COVID-19 is lowered from 270 yuan/bottle to about 175 yuan/bottle.
On June 8th, 65438+1October 8th, the person in charge of the Drug Administration Department of the National Medical Insurance Bureau introduced that the negotiation between Azifu Tablets and Qingfei Jiedu Granules was successful, but the price quoted by Pfizer was too high, but the price of ciclovir failed. The person in charge said that although paciclovir was not included in the medical insurance catalogue through negotiation, according to the Notice on Optimizing Medical Insurance Policies for Patients with Infectious Diseases in novel coronavirus after Implementing Class B Management recently issued by the National Medical Insurance Bureau and relevant departments, all therapeutic drugs in novel coronavirus's infection diagnosis and treatment plan, including paciclovir, afuddin tablets, Chanlawei capsules, cold-dispelling and dehumidification granules, will be temporarily paid by medical insurance until 2023.
In addition, after Afuddin Tablets and Qingfei Paidu Granules were included in the national medical insurance drug list through this negotiation, there were more than 600 kinds of drugs in the national medical insurance drug list for treating symptoms such as fever and cough in COVID-19.
Two new indications were added to domestic PD- 1.
At present, four domestic PD- 1 products have been included in the medical insurance, and the medical insurance negotiations mainly focus on adding new indications. Up to now, 13 PD- 1 antibody in China has been approved to enter the preliminary examination list and participate in the negotiation of increasing the indications of varieties in the Catalogue.
Earlier, some media said that the above-mentioned four domestic PD- 1 were not included in medical insurance, with a total of 12 indications, involving nasopharyngeal carcinoma, esophageal squamous cell carcinoma, adenocarcinoma at the junction of stomach and esophagus, and non-small cell lung cancer. Among them, esophageal squamous cell carcinoma is the indication declared by four enterprises in this medical insurance catalogue negotiation.
According to the published medical insurance catalogue, the paper notes that Cindilizumab of Cinda Bio has been included in two new first-line treatment indications for gastric cancer and esophageal cancer this year. This time, Cindilizumab became the only PD- 1 inhibitor with five first-line indications included in the national medical insurance catalogue.
Professor Lin Shen, director of the Department of Gastroenterology, Peking University Cancer Hospital, said that immunotherapy has played an increasingly important role in the field of tumor treatment in recent years. Clinical studies have found that, on the whole, patients with esophageal cancer are not limited by the expression level of PD- 1 antibody, and can all benefit from immunotherapy, which undoubtedly gives clinicians more treatment options. Indications such as esophageal squamous cell carcinoma are included in the new national medical insurance catalogue, and the drug burden of patients will be further reduced.
High-priced anticancer drugs failed to enter the medical insurance catalogue
It is worth mentioning that whether the "one million and one million needles" CAR-T therapy can be successfully negotiated in this medical insurance catalogue adjustment has attracted much attention from the outside world. This year, Yao Mingjianuo's Ruiqilong injection was on the negotiation list, but failed to enter the medical insurance catalogue through negotiation.
In addition to CAR-T therapy, ADC drugs are known as "smart biological missiles" and "panacea" in the field of tumor treatment. In recent years, this kind of drugs has become a hot spot in the field of medicine.
Up to now, there are five kinds of ADC drugs approved for marketing in China, including EMIzumab from Roche, Vebtuximab from Takeda, Ogayizumab from Pfizer/Wyeth, Vedixituzumab from Rongchang Bio and R0 Wa Tozumab from Genting New Medicine. 202 1, the camera successfully negotiated to enter the national medical insurance catalogue; The virtuximab negotiation failed, and Emetizumab did not enter the preliminary list.
According to the new national medical insurance catalogue, in this negotiation, Roche's imazumab, Takeda Pharmaceutical's Vebtuximab and Rongchang Bio's Vedixituzumab were successfully negotiated and appeared in the medical insurance catalogue.
Seven kinds of drugs for rare diseases are included in the medical insurance catalogue.
According to the press conference of the National Medical Insurance Bureau, 24 major domestic innovative drugs were included in the negotiations, and finally 20 drugs including Orobatinib were successfully negotiated. At the same time, 7 drugs for rare diseases, 22 drugs for children and 2 essential drugs were successfully listed in the catalogue, and the level of drug protection in key areas was further improved.
202 1, SMA therapeutic drug Nocichine sodium and other seven rare diseases were successfully negotiated and included in the national medical insurance, with an average price reduction of 65%. In 2022, there were 9 rare disease drugs/kloc-0 in the preliminary list, including Gao Xue's disease type I iminosidase for injection by Sanofi, and Agarase β for Fabry's disease injection; Ranalizumab for treating hereditary angioedema and Veracruz α for injection for treating Gaucher's disease; Roche's SMA therapeutic drug risperidone oral liquid powder and so on.
According to reports, at present, China's medical insurance catalogue has included 52 rare diseases, covering 27 rare diseases. Among them, since the establishment of the National Medical Insurance Bureau, 26 kinds of drugs for rare diseases have been added through negotiations, with an average decline of 53%, and the price reduction has been superimposed on medical insurance reimbursement, effectively reducing the burden on insured patients.
65438+ 10 18, Huang Xinyu said that as long as the price of rare disease drugs can be negotiated, the medical insurance catalogue is very active, and he wants to include rare disease drugs in the catalogue, and he attaches great importance to rare disease drugs in the early review and later calculation.
According to the new medical insurance catalogue, Ranalizumab for treating hereditary angioedema, Orfatomuzumab for treating adult recurrent multiple sclerosis, risperidone oral solution powder, etc. , appear in the medical insurance catalogue. Many domestic innovative drugs have been included in this round of negotiations. Among them, two products, Hengrui Pharma AR inhibitor Rivetamide Tablets and Redirecting Medicine, have also been included in the medical insurance drug list.